Every few months for the past three years, Jeff Vierstra has been receiving infusions in his spine that target and disable a ...

The PREVAiLS study, believed to be the only recruiting phase 3 ALS trial, aims to slow disease progression and preserve ...

ALS is life‑changing, but new treatments, specialized care, and innovative research are bringing real hope. See how advances at University of Utah Health are shaping the future of ALS care.

The ALS therapy candidate AP-101 significantly extended patient survival and delayed the need for respiratory support in a ...

One ALS patient received TRE-515 under the FDA program last year, and early signs suggest the therapy may help stabilize ...

A new global initiative launched today aims to close a critical gap in ALS/MND drug discovery - current cell models used for ...

In March 2024, Kayla Gonzalez started having an odd sensation behind her right kneecap. At first, she didn’t think much of it. Then, the feeling started to spread. Soon, she had weakness in her calf, ...

NAARDEN, The Netherlands & WALTHAM, Mass. & BARCELONA, Spain, March 30, 2026--Prilenia Therapeutics B.V. and Ferrerii today announced the first enrollment in the pivotal, 500-participant, randomized, ...

Amyotrophic lateral sclerosis (ALS) is a rapidly progressive, invariably fatal neurological disease. Individuals affected by ALS include those living with ALS, their caregivers, presymptomatic ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has approved RELYVRIO™ ...

The National Academies of Sciences, Engineering, and Medicine are private, nonprofit institutions that provide expert advice on some of the most pressing challenges facing the nation and world. Our ...